Technical analysis of Annovis Bio, Inc. (ANVS): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases.
Price Performance
| 1 month | -42.22% |
| 3 months | -40.57% |
| Year-to-date | -69.94% |
| 1 year | -55.17% |
| 3 years | -89.90% |
| 5 years | -96.90% |
52-Week Range
| 52-week High | $5.50 |
| 52-week Low | $1.04 |
| Avg Volume (90d) | 1.0M |
Technical Indicators
| SMA 50 | $1.68 |
| SMA 200 | $2.36 |
| Beta | 1.36 |
| 30-day Volatility (annualised) | 75.8% |
| Price vs SMA 50 | -38.1% |
| Price vs SMA 200 | -56.0% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $2.10 | |
| 2025-11 | $5.10 | +142.9% |
| 2025-12 | $3.46 | -32.2% |
| 2026-01 | $2.70 | -22.0% |
| 2026-02 | $2.68 | -0.7% |
| 2026-03 | $2.23 | -16.8% |
| 2026-04 | $1.97 | -11.7% |
| 2026-05 | $1.92 | -2.5% |
| 2026-06 | $1.86 | -3.1% |
| 2026-07 | $1.75 | -5.9% |
| 2026-08 | $1.72 | -1.7% |
| 2026-09 | $1.04 | -39.5% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $1.04 |
| Market Cap | $44M |
| Exchange | NYSE |
| Country | US |
Valuation Ratios
| Price / Book | -7.41 |
| EV / EBITDA | -0.82 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 2.95 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -4.44 |